MAIA Biotechnology Inc (MAIA)
2.94
+0.10
(+3.52%)
USD |
NYAM |
May 15, 14:22
MAIA Biotechnology Research and Development Expense (Quarterly): 3.717M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.717M |
September 30, 2023 | 2.600M |
June 30, 2023 | 2.599M |
March 31, 2023 | 2.145M |
December 31, 2022 | 2.393M |
September 30, 2022 | 2.343M |
Date | Value |
---|---|
June 30, 2022 | 2.120M |
March 31, 2022 | 2.048M |
December 31, 2021 | 1.465M |
September 30, 2021 | 1.082M |
June 30, 2021 | 0.644M |
March 31, 2021 | 0.2628M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.2628M
Minimum
Mar 2021
3.717M
Maximum
Dec 2023
1.952M
Average
2.132M
Median
Research and Development Expense (Quarterly) Benchmarks
Cyclacel Pharmaceuticals Inc | 3.518M |
Avid Bioservices Inc | -- |
Oragenics Inc | 11.04M |
NeuBase Therapeutics Inc | 0.3876M |
Viking Therapeutics Inc | 24.10M |